| IOVANCE BIOTHERAPEUTICS |
| USA |
| Gesundheit |
| US4622601007 / A2DT49 |
| 2LB (Frankfurt) / IOVA (NASDAQ) |
| FRA:2LB, ETR:2LB, 2LB:GR, NASDAQ:IOVA |
| - |
| https://www.iovance.com/ |
|
Iovance Biotherapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing tumor infiltrating lymphocyte, or TIL, cell therapies for cancer. Its current portfolio centers on Amtagvi, an individualized cell ..
>Volltext.. |
| 4374.08 Mio. EUR |
| 4154 Mio. EUR |
| 285.22 Mio. EUR |
| -220.39 Mio. EUR |
| -254.15 Mio. EUR |
| -0.63 EUR |
| 40.38 Mio. EUR |
| 97.24 Mio. EUR |
| -231.91 Mio. EUR |
| 2.79 |
| 38.76% |
| 23.41% |
| - |
| - |
| - |
| - |
| IOVANCE |
| 29.09.26 |
|